Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Hypermethylation of the suppressor of cytokine signalling‐1 (SOCS‐1) in myelodysplastic syndrome

Hypermethylation of the suppressor of cytokine signalling‐1 (SOCS‐1) in myelodysplastic syndrome Transcriptional silencing because of hypermethylation is now recognised to be a hallmark of human tumours. In contrast to acute myeloid leukaemia (AML), comparably little is known about aberrant methylation in myelodysplastic syndrome (MDS), a heterogeneous clonal stem cell disorder with a risk of transformation into secondary AML of up to 30%. Recent evidence demonstrates that suppressor of cytokine signalling SOCS‐1, a negative regulator of cytokine pathways, may act as a tumour suppressor gene, and inactivation because of hypermethylation was shown in various malignancies. Employing a newly developed quantitative real‐time polymerase chain reaction‐based methylation assay we analysed, for the first time, SOCS‐1 methylation in MDS and found disease‐specific hypermethylation in 27 of 86 MDS patients (31%). Demethylation experiments provided direct evidence that aberrant methylation of SOCS‐1 induces transcriptional silencing in myeloid cells. In addition, by analysing the expression of signal transducers and activators of transcription (STAT)‐induced genes we provide for the first time evidence that the activity of the Janus kinase/STAT pathway is increased in primary patient samples showing SOCS‐1 hypermethylation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Haematology Wiley

Hypermethylation of the suppressor of cytokine signalling‐1 (SOCS‐1) in myelodysplastic syndrome

Download PDF
9 pages

Loading next page...
 
/lp/wiley/hypermethylation-of-the-suppressor-of-cytokine-signalling-1-socs-1-in-Rv8ghizgvn

References (61)

Publisher
Wiley
Copyright
Copyright © 2005 Wiley Subscription Services
ISSN
0007-1048
eISSN
1365-2141
DOI
10.1111/j.1365-2141.2005.05590.x
pmid
16029449
Publisher site
See Article on Publisher Site

Abstract

Transcriptional silencing because of hypermethylation is now recognised to be a hallmark of human tumours. In contrast to acute myeloid leukaemia (AML), comparably little is known about aberrant methylation in myelodysplastic syndrome (MDS), a heterogeneous clonal stem cell disorder with a risk of transformation into secondary AML of up to 30%. Recent evidence demonstrates that suppressor of cytokine signalling SOCS‐1, a negative regulator of cytokine pathways, may act as a tumour suppressor gene, and inactivation because of hypermethylation was shown in various malignancies. Employing a newly developed quantitative real‐time polymerase chain reaction‐based methylation assay we analysed, for the first time, SOCS‐1 methylation in MDS and found disease‐specific hypermethylation in 27 of 86 MDS patients (31%). Demethylation experiments provided direct evidence that aberrant methylation of SOCS‐1 induces transcriptional silencing in myeloid cells. In addition, by analysing the expression of signal transducers and activators of transcription (STAT)‐induced genes we provide for the first time evidence that the activity of the Janus kinase/STAT pathway is increased in primary patient samples showing SOCS‐1 hypermethylation.

Journal

British Journal of Haematology – Wiley

Published: Jan 1, 2005

Keywords: ; ; ; ;

There are no references for this article.